Immunogenicity of SakSTAR variants in patients with peripheral arterial occlusion
| Compound . | n . | Neutralizing activity . | Specific IgG (μg/mL) . | |
|---|---|---|---|---|
| (μg/mL) . | n with >5 μg/mL . | |||
| SakSTAR | 70 | 12 (4.0-100) | 57 | 380 (81-1850) |
| SY15 | 6 | 9.3 (0.1-19) | 3 | 400 (32-740) |
| SY19 | 18 | 1.5 (0.2-7.0) | 5 | 110 (37-260) |
| SY46 | 6 | 12 (0.9-42) | 3 | 1800 (140-7100) |
| SY118 | 6 | 27 (17-49) | 5 | 2000 (1300-3600) |
| SY141 | 6 | 1.7 (0.1-8.3) | 2 | 53 (4.5-1800) |
| SY145 | 7 | 1.6 (1.2-49) | 2 | 540 (110-790) |
| SY151 | 6 | 33 (3.5-40) | 4 | 1900 (310-3500) |
| SY155 | 5 | 15 (6.6-63) | 4 | 360 (160-1500) |
| Total mutants | 60 | 4.4 (0.3-49) | 28 | 270 (32-2600) |
| Compound . | n . | Neutralizing activity . | Specific IgG (μg/mL) . | |
|---|---|---|---|---|
| (μg/mL) . | n with >5 μg/mL . | |||
| SakSTAR | 70 | 12 (4.0-100) | 57 | 380 (81-1850) |
| SY15 | 6 | 9.3 (0.1-19) | 3 | 400 (32-740) |
| SY19 | 18 | 1.5 (0.2-7.0) | 5 | 110 (37-260) |
| SY46 | 6 | 12 (0.9-42) | 3 | 1800 (140-7100) |
| SY118 | 6 | 27 (17-49) | 5 | 2000 (1300-3600) |
| SY141 | 6 | 1.7 (0.1-8.3) | 2 | 53 (4.5-1800) |
| SY145 | 7 | 1.6 (1.2-49) | 2 | 540 (110-790) |
| SY151 | 6 | 33 (3.5-40) | 4 | 1900 (310-3500) |
| SY155 | 5 | 15 (6.6-63) | 4 | 360 (160-1500) |
| Total mutants | 60 | 4.4 (0.3-49) | 28 | 270 (32-2600) |
Data represent median and 15 to 85 percentile range frequencies or mean ± SEM. Code identification in Table 3.